Sanofi logo

Sanofi

SNY | NASDAQ
Chart Builder DCF Calculator
$44.34
+$1.21 (+2.81%)
At close: Oct 30, 2026, 4:00 PM ET
$44.54
+$0.20 (+0.45%)
Pre-market: Nov 2, 2026, 6:26 AM ET

Company Profile

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Key Executives

Name Position
Belen Garijo Lopez Chief Executive Officer & Director
François-Xavier Roger Executive Vice President & Chief Financial Officer
Veronique Jaillet Executive VP & Interim Chief People Officer
Emmanuel Frenehard Executive VP & Chief Digital Officer
Erik Wallström Head of Therapeutic Area - Neurology Development
Fabrizio Gaudi Head of Austrian, German & Swiss Operations
Houman Ashrafian Executive VP & Head of Research & Development
Jamie Haney Executive Vice President & General Counsel
Karin Knobe TA Head of Rare Diseases & Rare Blood Disorders Development
Madeleine Roach Executive Vice President & Head of Business Operations
Michael Quigley Chief Scientific Officer & Head of Research
Olivier Charmeil Executive Vice President of General Medicines
Olivier Klaric Senior Vice President of Financing & Treasury
Pablo Sardi TA Head of Rare & Neurologic Diseases Research
Pierre Chancel Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing
Roy Papatheodorou Executive Vice President & General Counsel
Thomas Kudsk Larsen Head of Investor Relations & General Medicines
Thomas Triomphe Executive Vice President of Vaccines

Latest SEC Filings

Date Type Title
Oct 01, 2026 6-K Filing
Sep 17, 2026 6-K Filing
Aug 25, 2026 N-PX Filing
Aug 12, 2026 4 Filing
Aug 12, 2026 3 Filing
Aug 07, 2026 4 Filing
Aug 06, 2026 6-K Filing
Aug 04, 2026 3 Filing
Jul 30, 2026 6-K Filing
Jul 30, 2026 6-K Filing
View All SEC Filings ➞
Sanofi
Sanofi logo
Country France
IPO Date Jul 1, 2002
Industry Drug Manufacturers - General
Sector Healthcare
Employees 76,493
CEO Belén Garijo López

Contact Details

46, avenue de la Grande ArmEe Paris, IF 75017 France

Stock Details

Ticker Symbol SNY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001121404
CUSIP Number 80105N105
ISIN Number US80105N1054
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.